skip to content
  1. Home
  2. >
  3. Investment Q&A
You can view 3 more answers this month. Sign up for a free trial for unlimited access.

Investment Q&A

Not investment advice or solicitation to buy/sell securities. Do your own due diligence and/or consult an advisor.

Q: In 2016 I had significant realized capital gains as I sold off shares to re-balance my portfolio. Currently I am in a loss position with the above mentioned companies. I was thinking of selling shares in these six companies to help offset the realized capital gains. Which of these shares do you think I should buy back after 30 days to avoid the superficial capital loss? Normally I would not be selling them, but for tax purposes I am contemplating doing so. AAPL makes up a significant part of my Info Technology sector and GILD is my only exposure to the health care sector. If I do not buy back the other four companies it will not impact my asset mix in my portfolio significantly. Is this the right time of year to do tax loss selling for these companies?

Thank you
Read Answer Asked by Robert on September 09, 2016
Q: hello 5i team

Have been watching GILD for a while now as I think there is tremendous potential. Having said that today it was reported AbbVIE appears to have pulled a bit of a fast one on GILD by convincing the patent office they have invented a novel computer model to predict effective combination therapies. This has apparently convinced the patent office the very same patents applied for by GILD back in Sept actually belong to AbbVIE.

It was these very patents which gave GILD such a big upside moving forward but now it appears with AbbVie jumping into the picture the market is not looking favorably at GILD with it down almost 10% in 10 days and dropping.

Both are now suing each other.

Can you shed any light on all this for us and exactly what it means for GILD moving forward.

Thanks for all you do

gm
Read Answer Asked by Gord on November 14, 2014
Q: Gilead Science GILD.US had 2 pieces of good news today. UK government has approved its drug for Hepatitis C at the full price charged in the US. Roche had its patent challenge rejected. GILD has moved up by about 2% on this news and is up about 20% since the beginning of June. This is now about 10% of my portfolio.
I would be grateful for your comments.
Read Answer Asked by Graham on August 18, 2014
Looking for more? Sign up for a FREE 14 day trial! No credit card required

We invite you to sign up for a 14 day free trial of 5i Research!
Experience all the benefits and tools we have to offer; stock research, model portfolios, Q&A with our experts, and so much more. Join a community of like-minded investors today!